Ariad Starts New Trial, Endocyte Receives Orphan Drug Status and a Sell Recommendation
It's been a great week for our portfolio. Biotechnology companies we have picked are either starting new clinical trials or are nearing an FDA decision for commercialization. We'll also have more exciting news soon. This weekend, a big event is being held in Vienna by the European Society for Medical Oncology. Several of our companies will be presenting data there, and I hope to have information for you next week.
Endocyte (NASDAQ: ECYT), a recent addition to our portfolio, specializes in a new form of targeted therapy. Called SMDC (small molecule drug conjugate), it enjoys many of the benefits of antibody-targeted therapies, with the additional penetrating power of a small molecule.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.